Recent
Press Releases:
- Aug 22, 2008
- Feb 11, 2008
- Jan 25, 2008
- Jan 24, 2008
- Jan 17, 2008
- Jan 11, 2007
- Nov 15, 2006
- Oct 2, 2006
- Jul 5, 2006
- Apr 4, 2006
- Feb 16, 2006
- Jan 24, 2006
- Sep 14, 2005
- Aug 9, 2005
- May 13, 2005
- May 4, 2005
- March 22, 2005
Upcoming Events |
OFFICIAL RELEASE
Ash Access Technology, Inc.’s, Investigational
AAT-023 Therapy Produces Impressive Anti-Biofilm Results in Pre-clinical
Lab Tests
The Ability of AAT-023 to Completely Eradicate Biofilm and Deliver
Broadspectrum Antimicrobial Efficacy Creates a Powerful Combination
in the Fight against Catheter-Related Bloodstream Infections
Friday, May 13, 2005 2:07 PM
EDT - - - (Lafayette, Indiana) Ash Access Technology, Inc. revealed additional pre-clinical
laboratory results that demonstrated significant anti-biofilm properties
for its flagship investigational therapy, AAT-023. Earlier this
month, the company reported impressive, broad spectrum antimicrobial
efficacy as compared to a heparin arm against similar bacterial
strains in other pre-clinical testing. The ability of AAT-023 to
completely eradicate both gram positive and gram negative strains
of bacteria associated with CRBSI infections as well as eliminate
biofilm strengthens the product’s potential profile in making
a significant impact on the morbidity and mortality of patients
using catheters for vascular access in chronic and acute settings.
“We are very pleased with these initial anti-biofilm results
and plan to conduct additional AAT-023 studies in the future,” explained
Roland K. Winger, Vice President of Engineering and Quality Assurance. “Since
biofilm creates a friendly environment to host harmful bacteria associated
with catheter-related bloodstream infections (CRBSI), a key objective
in the design of AAT-023 was to prevent any biofilm growth. AAT-023’s
anti-biofilm attributes help us better understand the potential this
therapy has in the prevention of deadly and costly infections.” (A
table of some of these first anti-biofilm results are shown below.)
Biofilm Antimicrobial Effectiveness:
S. aureus Biofilm
Colonization
Inhibition and Elimination

“These results just add to our growing excitement about the
impact we expect AAT-023 to make towards saving lives threatened
by catheter-related bloodstream infections,” said Robert B.
Truitt, President and CEO of Ash Access Technology, Inc. “By
preventing biofilm buildup in catheters, and removing bacteria's
favorite colonization grounds, we would expect to see a significant
reduction in the number of infections, better treatment results as
well as a dramatic reduction in the billions of dollars estimated
to be lost to these infections every year. We intend to conduct our
pivotal clinical trial for AAT-023 in the coming months in hemodialysis
patients who are using a central venous catheter for their vascular
access, however, we also see tremendous applications of this technology
in a wide array of patient populations such as oncology patients
and in other acute care settings throughout a hospital.”
According to the Centers for Disease Control,
the magnitude of CRBSI in the U.S is significant with an estimated
200,000 to 400,000 episodes annually. Studies have shown that mortality
rates associated with CRBSI range from 12 – 25% while annual
healthcare costs for treating these infections may exceed $2 billion.
Ash Access Technology, Inc. is a privately-held
company founded to develop antimicrobial and vascular access technologies,
devices and methodologies to combat the deadly and expensive problem
of catheter-related bloodstream infections, with an emphasis on prevention.
Dr. Stephen A. Ash, Chairman and Director, Research and Development,
is a practicing Nephrologist with the Arnett Clinic in Lafayette,
Indiana, and is a world-recognized researcher and patent holder in
extracorporeal devices, sorbent chemistry, and vascular and peritoneal
access devices. Ash Access Technology is located in Lafayette, Indiana
in the INOK Business Center.
This press release contains forward-looking statements, which if
not based on historical facts, involve risks and uncertainties. Our
actual results may differ materially from the results or events stated
in the forward-looking statements, including, but not limited to,
certain events not within the Company's control. |